{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:35:55Z","timestamp":1787150155716,"version":"build-2736575974"},"reference-count":74,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"unspecified","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000835","name":"University of Bath","doi-asserted-by":"publisher","award":["University Research Studentship Award (URSA)"],"award-info":[{"award-number":["University Research Studentship Award (URSA)"]}],"id":[{"id":"10.13039\/501100000835","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bath Institute for Rheumatic Diseases","award":["RAG-WT-45-250801"],"award-info":[{"award-number":["RAG-WT-45-250801"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,7,21]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the prevalence of anti-drug antibodies (ADAs) in patients with psoriatic arthritis (PsA) treated with biological disease-modifying antirheumatic drugs (bDMARDs) and to evaluate associations with serum drug levels, clinical efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-guided systematic review was conducted. MEDLINE, Embase and Cochrane CENTRAL were searched from inception to September 2025. Randomised controlled trials and observational studies reporting ADA measurement in adults with PsA receiving bDMARDs were included. The risk of bias was assessed using the Cochrane Risk of Bias Tool 2 and the Risk of Bias in Non-randomised Studies of Interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>28 studies (19 randomised controlled trials and 9 observational studies) were included. ADA prevalence varied widely between bDMARDs and across studies of the same drug and was not directly comparable due to immunoassay heterogeneity. The highest ADA prevalence was observed with adalimumab, infliximab and golimumab followed by ustekinumab, ixekizumab, certolizumab pegol and guselkumab, while secukinumab and etanercept demonstrated very low or absent immunogenicity. Across tumour necrosis factor (TNF) inhibitor studies, ADAs were consistently associated with lower serum drug levels and reduced clinical response, while concomitant methotrexate was associated with lower ADA prevalence. In contrast, serum drug level and clinical outcome data for interleukin (IL)-17, IL-12\/23 and IL-23 inhibitors were limited or lacking. Immunogenicity-related adverse events were uncommon, and evidence was insufficient to establish an association with ADAs across bDMARDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ADA prevalence in PsA varies widely between bDMARDs and across studies of the same bDMARD. ADAs appear most clinically relevant for TNF inhibitors, whereas evidence for other biological classes remains limited. Immunoassay heterogeneity limits comparability, highlighting the need for standardised prospective studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD420251121662.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2026-007140","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:20:21Z","timestamp":1787149221000},"page":"e007140","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7890-6182","authenticated-orcid":false,"given":"James","family":"Kimpton","sequence":"first","affiliation":[{"name":"Department of Life Sciences, University of Bath, Bath, UK"},{"name":"Royal National Hospital for Rheumatic Diseases, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akpabio","family":"Akpabio","sequence":"additional","affiliation":[{"name":"Royal National Hospital for Rheumatic Diseases, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Watts","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Tansley","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Bath, Bath, UK"},{"name":"Royal National Hospital for Rheumatic Diseases, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Mathematical Sciences, University of Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"McHugh","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Bath, Bath, UK"},{"name":"Royal National Hospital for Rheumatic Diseases, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026081907201722000_12.3.e007140.1","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/rheumatology\/kead586","article-title":"The epidemiology of psoriatic arthritis in the UK: a health intelligence analysis of UK primary care electronic health records 1991\u20132020","volume":"63","author":"Druce","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026081907201722000_12.3.e007140.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker216"},{"key":"2026081907201722000_12.3.e007140.3","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1093\/rheumatology\/keac295","article-title":"The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs","volume":"61","author":"Tucker","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026081907201722000_12.3.e007140.4","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000880","article-title":"Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry","volume":"5","author":"Mease","year":"2019","journal-title":"RMD Open"},{"key":"2026081907201722000_12.3.e007140.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac676"},{"key":"2026081907201722000_12.3.e007140.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2007.07.011"},{"key":"2026081907201722000_12.3.e007140.7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","article-title":"Immunogenicity of biologic agents in rheumatology","volume":"17","author":"Strand","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2026081907201722000_12.3.e007140.8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket260"},{"key":"2026081907201722000_12.3.e007140.9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.09.041"},{"key":"2026081907201722000_12.3.e007140.10","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000404"},{"key":"2026081907201722000_12.3.e007140.11","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0231-8"},{"key":"2026081907201722000_12.3.e007140.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222155"},{"key":"2026081907201722000_12.3.e007140.13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.23098","article-title":"Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies","volume":"6","author":"Bitoun","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026081907201722000_12.3.e007140.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2010.03.012"},{"key":"2026081907201722000_12.3.e007140.15","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1048411"},{"key":"2026081907201722000_12.3.e007140.16","unstructured":"Veritas Health Innovation . Covidence systematic review software. Melbourne, Australia"},{"key":"2026081907201722000_12.3.e007140.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026081907201722000_12.3.e007140.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026081907201722000_12.3.e007140.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108787"},{"key":"2026081907201722000_12.3.e007140.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205554"},{"key":"2026081907201722000_12.3.e007140.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140685"},{"key":"2026081907201722000_12.3.e007140.22","doi-asserted-by":"publisher","DOI":"10.1177\/0300060515593235"},{"key":"2026081907201722000_12.3.e007140.23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jbspin.2015.04.020","article-title":"The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a prospective multicentre study","volume":"83","author":"Hoxha","year":"2016","journal-title":"Joint Bone Spine"},{"key":"2026081907201722000_12.3.e007140.24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cyto.2017.02.015","article-title":"Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab","volume":"96","author":"Cludts","year":"2017","journal-title":"Cytokine"},{"key":"2026081907201722000_12.3.e007140.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190253"},{"key":"2026081907201722000_12.3.e007140.26","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/rheumatology\/kead525","article-title":"Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases","volume":"63","author":"Jyssum","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026081907201722000_12.3.e007140.27","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-2009-5","article-title":"Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study","volume":"21","author":"Gehin","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026081907201722000_12.3.e007140.28","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/03009742.2021.1875040","article-title":"Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study","volume":"50","author":"Gehin","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"2026081907201722000_12.3.e007140.29","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s10067-025-07307-0","article-title":"Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: \u201cearly therapeutic drug monitoring of adalimumab\u201d","volume":"44","author":"Ortiz-Fern\u00e1ndez","year":"2025","journal-title":"Clin Rheumatol"},{"key":"2026081907201722000_12.3.e007140.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"2026081907201722000_12.3.e007140.31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key309"},{"key":"2026081907201722000_12.3.e007140.32","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/acr.23905","article-title":"Efficacy and safety of intravenous golimumab through one year in patients with active psoriatic arthritis","volume":"72","author":"Husni","year":"2020","journal-title":"Arthritis Care & Research"},{"key":"2026081907201722000_12.3.e007140.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058339"},{"key":"2026081907201722000_12.3.e007140.34","article-title":"FRI0188 The impact of immunogenicity on drug safety profile [abstract]","volume":"72","author":"Garc\u00eas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026081907201722000_12.3.e007140.35","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2665-9913(23)00341-7","article-title":"Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials","volume":"6","author":"Brun","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026081907201722000_12.3.e007140.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202646"},{"key":"2026081907201722000_12.3.e007140.37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190116"},{"key":"2026081907201722000_12.3.e007140.38","article-title":"Anti-drug antibodies, efficacy, and impact of concomitant methotrexate in ixekizumab-treated patients with psoriatic arthritis [abstract]","volume":"70","author":"Ritchlin","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026081907201722000_12.3.e007140.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60140-9"},{"key":"2026081907201722000_12.3.e007140.40","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1093\/rheumatology\/kead177","article-title":"The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate","volume":"62","author":"Mojtahed Poor","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026081907201722000_12.3.e007140.41","first-page":"32","article-title":"Immunogenicity and clinical relevance of ustekinumab in two phase 3 studies in patients with active psoriatic arthritis","volume":"2","author":"Zhu","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026081907201722000_12.3.e007140.42","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201532"},{"key":"2026081907201722000_12.3.e007140.43","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.ard.2025.08.006","article-title":"Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study","volume":"84","author":"Mease","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026081907201722000_12.3.e007140.44","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026081907201722000_12.3.e007140.45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2026081907201722000_12.3.e007140.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2026081907201722000_12.3.e007140.47","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1551-x"},{"key":"2026081907201722000_12.3.e007140.48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/acr.23111","article-title":"Secukinumab for long-term treatment of psoriatic arthritis: a two-year follow-up from a phase III, randomized, double-blind, placebo-controlled study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026081907201722000_12.3.e007140.49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/acr2.11097","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatology"},{"key":"2026081907201722000_12.3.e007140.50","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2026081907201722000_12.3.e007140.51","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"The Lancet"},{"key":"2026081907201722000_12.3.e007140.52","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170429"},{"key":"2026081907201722000_12.3.e007140.53","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/key182","article-title":"Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2026081907201722000_12.3.e007140.54","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s10067-022-06218-8","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results","volume":"41","author":"Coates","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2026081907201722000_12.3.e007140.55","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1093\/rheumatology\/kez684","article-title":"Ixekizumab treatment of biologic-na\u00efve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)","volume":"59","author":"Chandran","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026081907201722000_12.3.e007140.56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"2026081907201722000_12.3.e007140.57","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"2026081907201722000_12.3.e007140.58","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"The Lancet"},{"key":"2026081907201722000_12.3.e007140.59","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"The Lancet"},{"key":"2026081907201722000_12.3.e007140.60","doi-asserted-by":"publisher","DOI":"10.1002\/art.34436"},{"key":"2026081907201722000_12.3.e007140.61","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1334"},{"key":"2026081907201722000_12.3.e007140.62","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00559-1"},{"key":"2026081907201722000_12.3.e007140.63","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.3.11641"},{"key":"2026081907201722000_12.3.e007140.64","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00776-6"},{"key":"2026081907201722000_12.3.e007140.65","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cei.12742","article-title":"From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals","volume":"184","author":"Gunn","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"2026081907201722000_12.3.e007140.66","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fimmu.2015.00152","article-title":"Immunogenicity of anti-TNF-\u03b1 biotherapies: I. Individualized medicine based on immunopharmacological evidence","volume":"6","author":"Bendtzen","year":"2015","journal-title":"Front Immunol"},{"key":"2026081907201722000_12.3.e007140.67","doi-asserted-by":"publisher","DOI":"10.2165\/11535960-000000000-00000"},{"key":"2026081907201722000_12.3.e007140.68","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/cts.12738","article-title":"Early adalimumab and anti-adalimumab antibody levels for prediction of primary nonresponse in ankylosing spondylitis patients","volume":"13","author":"Ding","year":"2020","journal-title":"Clin Transl Sci"},{"key":"2026081907201722000_12.3.e007140.69","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/03009742.2018.1433232","article-title":"Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis","volume":"47","author":"Siljehult","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"2026081907201722000_12.3.e007140.70","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.jaip.2018.04.007","article-title":"The kinetics of antidrug antibodies, drug levels, and clinical outcomes in infliximab-exposed patients with immune-mediated disorders","volume":"6","author":"Nencini","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026081907201722000_12.3.e007140.71","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1208\/s12248-017-0148-7","article-title":"Drug target interference in immunogenicity assays: recommendations and mitigation strategies","volume":"19","author":"Zhong","year":"2017","journal-title":"AAPS J"},{"key":"2026081907201722000_12.3.e007140.72","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01365","article-title":"Drug tolerant anti-drug antibody assay for infliximab treatment in clinical practice identifies positive cases earlier","volume":"11","author":"Kharlamova","year":"2020","journal-title":"Front Immunol"},{"key":"2026081907201722000_12.3.e007140.73","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.170"},{"key":"2026081907201722000_12.3.e007140.74","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1136\/annrheumdis-2018-213299","article-title":"Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies","volume":"77","author":"van Schie","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2026-007140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:20:28Z","timestamp":1787149228000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2026-007140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":74,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2026-007140"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2026-007140","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}